Since CT and BAL are extremely difficult to do in patients with life-threatening COVID-19, mycological data collection is essential to allow IPA diagnosis. We strongly support adding β-D-glucan in serum and qPCR in serum and respiratory specimens to the accepted mycological work-up (ie, BAL culture and galactomannan testing)4, 6 until the most sensitive and specific biomarkers are identified in this setting. Serum galactomannan was negative in eight of nine (89%) patients, suggesting a lesser degree of Aspergillus invasiveness or early IPA diagnosis, since respiratory specimens were obtained shortly after intubation. Galactomannan was negative in our two patients receiving hydroxychloroquine, which is thought to have a negative effect on this measurement.9